retatrutide triple agonist glp-1 gip glucagon ly3437943 Retatrutide (GLP-1/GIP/Glucagon) Injections

Retatrutide. The triple agonist that's redefining metabolic research. 🧬 One compound. Three receptors. Unprecedented research potential. GIP → insulin response research GLP-1 → appetite suppression studies Glucagon → energy expenditure modulation No

23.33

★★★★☆4.8 (126)

retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP-1 receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter

24.96

★★★★★4.9 (98)

Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair

23.31

★★★★★5.0 (157)

RETATRUTIDE — The Triple Agonist, This is the most powerful weight-loss compound ever tested in clinical trials. Retatrutide (LY3437943) is the first-ever triple receptor agonist, simultaneously

20.41

★★★★★4.7 (84)

The power of three: Retatrutide's role in modern obesity and diabetes therapy

25.96

★★★★★4.9 (203)

LY3437943 in healthy participants in a phase 1 single ascending dose

24.08

★★★★★5.0 (176)

🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in

21.75

★★★★★4.8 (132)